BioXcel Therapeutics files 8-K with cost reduction, governance shift

Monday's 24-hour filing volume: 190 8-Ks, 10 424B5s, 2 S-3s.

Top 3

• BioXcel Therapeutics (CIK 1720893) — 8-K filed 2026-09-01 07:01 ET with Items 2.03 (creation of direct financial obligation) and 3.01 (material agreement). Item 2.03 contains buried 1.03 language (bankruptcy/receivership), while 3.01 buries 1.01 and 1.03 detail.
• Cenntro Inc. (CIK 1707919) — 8-K filed 2026-08-31 16:30 ET flagging Items 1.01 (material agreement), 3.02 (unregistered sales), and 9.01 (financial statements/exhibits). Unregistered sales disclosure with governance documentation buried in exhibits.
• Victory Capital Holdings, Inc. (CIK 1570827) — 8-K filed 2026-08-31 16:50 ET covering Items 1.01, 3.02, and 9.01. Material agreement and unregistered sales activity with internal agreement details sequestered in exhibits.

Paid subscribers see 7 more flagged filings + sector signals — upgrade for $9/mo: https://filingfirehose.com/daily/upgrade

FilingFirehose Daily · 2026-09-01